Form 8-K - Current report:
SEC Accession No. 0001356576-24-000069
Filing Date
2024-12-20
Accepted
2024-12-20 16:10:58
Documents
18
Period of Report
2024-12-19
Items
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K supn-20241219.htm   iXBRL 8-K 28909
2 EX-14.1 ex141-codeofethicsandbusin.htm EX-14.1 107335
6 image_0.jpg GRAPHIC 7100
7 image_1.jpg GRAPHIC 185
8 image_2.jpg GRAPHIC 74905
9 image_3.jpg GRAPHIC 57680
  Complete submission text file 0001356576-24-000069.txt   475214

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT supn-20241219.xsd EX-101.SCH 1798
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT supn-20241219_lab.xml EX-101.LAB 21884
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT supn-20241219_pre.xml EX-101.PRE 12522
21 EXTRACTED XBRL INSTANCE DOCUMENT supn-20241219_htm.xml XML 2727
Mailing Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850
Business Address 9715 KEY WEST AVENUE ROCKVILLE MD 20850 301-838-2500
SUPERNUS PHARMACEUTICALS, INC. (Filer) CIK: 0001356576 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35518 | Film No.: 241568042
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)